{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:26:06Z","timestamp":1793395566235,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2018Y0037\u30012021J01761"],"award-info":[{"award-number":["2018Y0037\u30012021J01761"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian Medical Innovation Project","award":["2019-CX-19"],"award-info":[{"award-number":["2019-CX-19"]}]},{"name":"Startup Fund for scientific research, Fujian Medical University","award":["2019QH1269"],"award-info":[{"award-number":["2019QH1269"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13318-022-00807-3","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T21:03:40Z","timestamp":1670533420000},"page":"89-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetic Analysis for Model-Based Therapeutic Drug Monitoring of Tacrolimus in Chinese Han Heart Transplant Patients"],"prefix":"10.1007","volume":"48","author":[{"given":"Yu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiana","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"issue":"10","key":"807_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.healun.2021.07.015","volume":"40","author":"KK Khush","year":"2021","unstructured":"Khush KK, Hsich E, Potena L, Cherikh WS, Chambers DC, Harhay MO, et\u00a0al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult heart transplantation report\u20142021; focus on recipient characteristics. J Heart Lung Transplant. 2021;40(10):1035\u201349. https:\/\/doi.org\/10.1016\/j.healun.2021.07.015.","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"807_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1586\/1744666x.2016.1123093","volume":"12","author":"JR Scalea","year":"2016","unstructured":"Scalea JR, Levi ST, Ally W, Brayman KL. Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Expert Rev Clin Immunol. 2016;12(3):333\u201342. https:\/\/doi.org\/10.1586\/1744666x.2016.1123093.","journal-title":"Expert Rev Clin Immunol"},{"issue":"9","key":"807_CR3","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1111\/ajt.13309","volume":"15","author":"MA Sikma","year":"2015","unstructured":"Sikma MA, van Maarseveen EM, van de Graaf EA, Kirkels JH, Verhaar MC, Donker DW, et\u00a0al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation. Am J Transplant. 2015;15(9):2301\u201313. https:\/\/doi.org\/10.1111\/ajt.13309.","journal-title":"Am J Transplant"},{"issue":"1","key":"807_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00007691-199902000-00002","volume":"21","author":"MB Regazzi","year":"1999","unstructured":"Regazzi MB, Rinaldi M, Molinaro M, Pellegrini C, Calvi M, Arbustini E, et\u00a0al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients. Ther Drug Monit. 1999;21(1):2\u20137. https:\/\/doi.org\/10.1097\/00007691-199902000-00002.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"807_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13318-019-00591-7","volume":"45","author":"MA Sikma","year":"2020","unstructured":"Sikma MA, Hunault CC, Van Maarseveen EM, Huitema ADR, Van de Graaf EA, Kirkels JH, et\u00a0al. High variability of whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation. Eur J Drug Metab Pharmacokinet. 2020;45(1):123\u201334. https:\/\/doi.org\/10.1007\/s13318-019-00591-7.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"807_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40262-019-00846-1","volume":"59","author":"MA Sikma","year":"2020","unstructured":"Sikma MA, Hunault CC, Huitema ADR, De Lange DW, Van Maarseveen EM. Clinical pharmacokinetics and impact of hematocrit on monitoring and dosing of tacrolimus early after heart and lung transplantation. Clin Pharmacokinet. 2020;59(4):403\u20138. https:\/\/doi.org\/10.1007\/s40262-019-00846-1.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"807_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/ftd.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et\u00a0al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307. https:\/\/doi.org\/10.1097\/ftd.0000000000000640.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"807_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/00498254.2019.1631505","volume":"50","author":"DD Wang","year":"2020","unstructured":"Wang DD, Chen X, Fu M, Zheng QS, Xu H, Li ZP. Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica. 2020;50(4):371\u20139. https:\/\/doi.org\/10.1080\/00498254.2019.1631505.","journal-title":"Xenobiotica"},{"key":"807_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115000","volume":"396","author":"I Hannachi","year":"2020","unstructured":"Hannachi I, Ben Fredj N, Chadli Z, Ben Fadhel N, Ben Romdhane H, Touitou Y, et\u00a0al. Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant. Toxicol Appl Pharmacol. 2020;396: 115000. https:\/\/doi.org\/10.1016\/j.taap.2020.115000.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11","key":"807_CR10","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40262-019-00771-3","volume":"58","author":"Y Rong","year":"2019","unstructured":"Rong Y, Mayo P, Ensom MHH, Kiang TKL. Population pharmacokinetics of mycophenolic acid co-administered with tacrolimus in corticosteroid-free adult kidney transplant patients. Clin Pharmacokinet. 2019;58(11):1483\u201395. https:\/\/doi.org\/10.1007\/s40262-019-00771-3.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"807_CR11","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1111\/bcp.13952","volume":"85","author":"Z Lu","year":"2019","unstructured":"Lu Z, Bonate P, Keirns J. Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. Br J Clin Pharmacol. 2019;85(8):1692\u2013703. https:\/\/doi.org\/10.1111\/bcp.13952.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"807_CR12","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1111\/bcp.14842","volume":"87","author":"LC Martial","year":"2021","unstructured":"Martial LC, Biewenga M, Ruijter BN, Keizer R, Swen JJ, van Hoek B, et\u00a0al. Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. Br J Clin Pharmacol. 2021;87(11):4262\u201372. https:\/\/doi.org\/10.1111\/bcp.14842.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"807_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.21037\/tp-20-84","volume":"9","author":"X Chen","year":"2020","unstructured":"Chen X, Wang DD, Xu H, Li ZP. Population pharmacokinetics and pharmacogenomics of tacrolimus in Chinese children receiving a liver transplant: initial dose recommendation. Transl Pediatr. 2020;9(5):576\u201386. https:\/\/doi.org\/10.21037\/tp-20-84.","journal-title":"Transl Pediatr."},{"issue":"6","key":"807_CR14","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/jcpt.13488","volume":"46","author":"CL Yang","year":"2021","unstructured":"Yang CL, Sheng CC, Liao GY, Su Y, Feng LJ, Xia Q, et\u00a0al. Genetic polymorphisms in metabolic enzymes and transporters have no impact on mycophenolic acid pharmacokinetics in adult kidney transplant patients co-treated with tacrolimus: a population analysis. J Clin Pharm Ther. 2021;46(6):1564\u201375. https:\/\/doi.org\/10.1111\/jcpt.13488.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"807_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/jcpt.12523","volume":"42","author":"HJ Zhang","year":"2017","unstructured":"Zhang HJ, Li DY, Zhu HJ, Fang Y, Liu TS. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. J Clin Pharm Ther. 2017;42(4):425\u201332. https:\/\/doi.org\/10.1111\/jcpt.12523.","journal-title":"J Clin Pharm Ther"},{"issue":"e1","key":"807_CR16","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1136\/ejhpharm-2018-001764","volume":"27","author":"Y Gong","year":"2020","unstructured":"Gong Y, Yang M, Sun Y, Li J, Lu Y, Li X. Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients. Eur J Hosp Pharm. 2020;27(e1):e12\u20138. https:\/\/doi.org\/10.1136\/ejhpharm-2018-001764.","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"807_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2217\/pgs-2018-0116","volume":"20","author":"Y Han","year":"2019","unstructured":"Han Y, Zhou H, Cai J, Huang J, Zhang J, Shi SJ, et\u00a0al. Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. Pharmacogenomics. 2019;20(1):21\u201335. https:\/\/doi.org\/10.2217\/pgs-2018-0116.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"807_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2017-000147","volume":"1","author":"JE Rower","year":"2017","unstructured":"Rower JE, Stockmann C, Linakis MW, Kumar SS, Liu X, Korgenski EK, et\u00a0al. Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model. BMJ Paediatr Open. 2017;1(1): e000147. https:\/\/doi.org\/10.1136\/bmjpo-2017-000147.","journal-title":"BMJ Paediatr Open."},{"issue":"4","key":"807_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/bcp.15091","volume":"88","author":"R Kirubakaran","year":"2022","unstructured":"Kirubakaran R, Hennig S, Maslen B, Day RO, Carland JE, Stocker SL. Evaluation of published population pharmacokinetic models to inform tacrolimus dosing in adult heart transplant recipients. Br J Clin Pharmacol. 2022;88(4):1751\u201372. https:\/\/doi.org\/10.1111\/bcp.15091.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"807_CR20","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00228-011-1010-y","volume":"67","author":"L Li","year":"2011","unstructured":"Li L, Li CJ, Zheng L, Zhang YJ, Jiang HX, Si-Tu B, et\u00a0al. Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study. Eur J Clin Pharmacol. 2011;67(8):787\u201395. https:\/\/doi.org\/10.1007\/s00228-011-1010-y.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"807_CR21","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2217\/pgs.10.105","volume":"11","author":"P Wang","year":"2010","unstructured":"Wang P, Mao Y, Razo J, Zhou X, Wong ST, Patel S, et\u00a0al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics. 2010;11(10):1389\u2013402. https:\/\/doi.org\/10.2217\/pgs.10.105.","journal-title":"Pharmacogenomics"},{"issue":"8","key":"807_CR22","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","volume":"51","author":"LK Kamdem","year":"2005","unstructured":"Kamdem LK, Streit F, Zanger UM, Brockm\u00f6ller J, Oellerich M, Armstrong VW, et\u00a0al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem. 2005;51(8):1374\u201381. https:\/\/doi.org\/10.1373\/clinchem.2005.050047.","journal-title":"Clin Chem"},{"issue":"2\u20133","key":"807_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0169-409x(97)00043-4","volume":"27","author":"MF Hebert","year":"1997","unstructured":"Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997;27(2\u20133):201\u201314. https:\/\/doi.org\/10.1016\/s0169-409x(97)00043-4.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"807_CR24","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/aps.2016.77","volume":"37","author":"S Liu","year":"2016","unstructured":"Liu S, Chen RX, Li J, Zhang Y, Wang XD, Fu Q, et\u00a0al. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients. Acta Pharmacol Sin. 2016;37(9):1251\u20138. https:\/\/doi.org\/10.1038\/aps.2016.77.","journal-title":"Acta Pharmacol Sin"},{"issue":"26","key":"807_CR25","doi-asserted-by":"publisher","first-page":"17882","DOI":"10.1074\/jbc.M601302200","volume":"281","author":"X Gu","year":"2006","unstructured":"Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, et\u00a0al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem. 2006;281(26):17882\u20139. https:\/\/doi.org\/10.1074\/jbc.M601302200.","journal-title":"J Biol Chem"},{"issue":"6","key":"807_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00228-014-1656-3","volume":"70","author":"I Lunde","year":"2014","unstructured":"Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, et\u00a0al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol. 2014;70(6):685\u201393. https:\/\/doi.org\/10.1007\/s00228-014-1656-3.","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"807_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00228-011-0993-8","volume":"67","author":"X Zhang","year":"2011","unstructured":"Zhang X, Wang Z, Fan J, Liu G, Peng Z. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur J Clin Pharmacol. 2011;67(8):803\u201313. https:\/\/doi.org\/10.1007\/s00228-011-0993-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"807_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/iji.12192","volume":"42","author":"Y Seyhun","year":"2015","unstructured":"Seyhun Y, Ciftci HS, Kekik C, Karadeniz MS, Tefik T, Nane I, et\u00a0al. Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-\u03b2, tumour necrosis factor-\u03b1 and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients. Int J Immunogenet. 2015;42(3):147\u201360. https:\/\/doi.org\/10.1111\/iji.12192.","journal-title":"Int J Immunogenet"},{"issue":"3","key":"807_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11095-019-2579-6","volume":"36","author":"T Lu","year":"2019","unstructured":"Lu T, Zhu X, Xu S, Zhao M, Huang X, Wang Z, et\u00a0al. Dosage optimization based on population pharmacokinetic analysis of tacrolimus in Chinese patients with nephrotic syndrome. Pharm Res. 2019;36(3):45. https:\/\/doi.org\/10.1007\/s11095-019-2579-6.","journal-title":"Pharm Res"},{"issue":"6","key":"807_CR30","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1053\/j.gastro.2017.08.037","volume":"153","author":"Y Toiyama","year":"2017","unstructured":"Toiyama Y, Okugawa Y, Tanaka K, Araki T, Uchida K, Hishida A, et\u00a0al. A panel of methylated microRNA biomarkers for identifying high-risk patients with ulcerative colitis-associated colorectal cancer. Gastroenterology. 2017;153(6):1634-46.e8. https:\/\/doi.org\/10.1053\/j.gastro.2017.08.037.","journal-title":"Gastroenterology"},{"issue":"4","key":"807_CR31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/bf01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503\u201312. https:\/\/doi.org\/10.1007\/bf01060893.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"11","key":"807_CR32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE. Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharmacokinet. 2020;59(11):1357\u201392. https:\/\/doi.org\/10.1007\/s40262-020-00922-x.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"807_CR33","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s40262-014-0189-3","volume":"53","author":"R Ogawa","year":"2014","unstructured":"Ogawa R, Stachnik JM, Echizen H. Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). Clin Pharmacokinet. 2014;53(12):1083\u2013114. https:\/\/doi.org\/10.1007\/s40262-014-0189-3.","journal-title":"Clin Pharmacokinet"},{"key":"807_CR34","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/pgpm.s337947","volume":"14","author":"F Cheng","year":"2021","unstructured":"Cheng F, Li Q, Wang J, Hu M, Zeng F, Wang Z, et\u00a0al. Genetic polymorphisms affecting tacrolimus metabolism and the relationship to post-transplant outcomes in kidney transplant recipients. Pharmgenomics Pers Med. 2021;14:1463\u201374. https:\/\/doi.org\/10.2147\/pgpm.s337947.","journal-title":"Pharmgenomics Pers Med."},{"issue":"8","key":"807_CR35","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","volume":"69","author":"V Guy-Viterbo","year":"2013","unstructured":"Guy-Viterbo V, Scohy A, Verbeeck RK, Reding R, Wallemacq P, Musuamba FT. Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol. 2013;69(8):1533\u201342. https:\/\/doi.org\/10.1007\/s00228-013-1501-0.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"807_CR36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","volume":"36","author":"TK Bergmann","year":"2014","unstructured":"Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit. 2014;36(1):62\u201370. https:\/\/doi.org\/10.1097\/FTD.0b013e31829f1ab8.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"807_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jcpt.12599","volume":"42","author":"B Chen","year":"2017","unstructured":"Chen B, Shi HQ, Liu XX, Zhang WX, Lu JQ, Xu BM, et\u00a0al. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther. 2017;42(6):679\u201388. https:\/\/doi.org\/10.1111\/jcpt.12599.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"807_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/bcp.12174","volume":"77","author":"MH Jalil","year":"2014","unstructured":"Jalil MH, Hawwa AF, McKiernan PJ, Shields MD, McElnay JC. Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Br J Clin Pharmacol. 2014;77(1):130\u201340. https:\/\/doi.org\/10.1111\/bcp.12174.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"807_CR39","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/fpc.0000000000000237","volume":"26","author":"FD Genvigir","year":"2016","unstructured":"Genvigir FD, Salgado PC, Felipe CR, Luo EY, Alves C, Cerda A, et\u00a0al. Influence of the CYP3A4\/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenet Genomics. 2016;26(10):462\u201372. https:\/\/doi.org\/10.1097\/fpc.0000000000000237.","journal-title":"Pharmacogenet Genomics"},{"issue":"3","key":"807_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/s0009-9236(03)00168-1","volume":"74","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et\u00a0al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74(3):245\u201354. https:\/\/doi.org\/10.1016\/s0009-9236(03)00168-1.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"807_CR41","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00228-008-0520-8","volume":"64","author":"XY Qiu","year":"2008","unstructured":"Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, et\u00a0al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2008;64(11):1069\u201384. https:\/\/doi.org\/10.1007\/s00228-008-0520-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"807_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1515\/dmpt-2016-0036","volume":"32","author":"EY Tamashiro","year":"2017","unstructured":"Tamashiro EY, Felipe CR, Genvigir FDV, Rodrigues AC, Campos AB, Hirata RDC, et\u00a0al. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients. Drug Metab Pers Ther. 2017;32(2):89\u201395. https:\/\/doi.org\/10.1515\/dmpt-2016-0036.","journal-title":"Drug Metab Pers Ther."},{"issue":"11","key":"807_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/gtmb.2017.0088","volume":"21","author":"F Liu","year":"2017","unstructured":"Liu F, Ou YM, Yu AR, Xiong L, Xin HW. Long-term influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 polymorphisms on tacrolimus concentration in Chinese renal transplant recipients. Genet Test Mol Biomarkers. 2017;21(11):663\u201373. https:\/\/doi.org\/10.1089\/gtmb.2017.0088.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"10","key":"807_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353. https:\/\/doi.org\/10.2165\/00003088-200443100-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"807_CR45","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","volume":"29","author":"MR Costanzo","year":"2010","unstructured":"Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et\u00a0al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914\u201356. https:\/\/doi.org\/10.1016\/j.healun.2010.05.034.","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"807_CR46","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1046\/j.1523-1755.2001.059002725.x","volume":"59","author":"CY Hsu","year":"2001","unstructured":"Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int. 2001;59(2):725\u201331. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.059002725.x.","journal-title":"Kidney Int"},{"issue":"2","key":"807_CR47","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","volume":"90","author":"E Comets","year":"2008","unstructured":"Comets E, Brendel K, Mentr\u00e9 F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90(2):154\u201366. https:\/\/doi.org\/10.1016\/j.cmpb.2007.12.002.","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"807_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/aps.2014.110","volume":"36","author":"Yan-xia Lu","year":"2015","unstructured":"Yan-xia, Lu Qing-hong, Su Ke-hua, Wu Yu-peng, Ren Liang, Li Tian-yan, Zhou Wei, Lu (2015) A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. Acta Pharmacologica Sinica 36(2) 281-288 https:\/\/doi.org\/10.1038\/aps.2014.110","journal-title":"Acta Pharmacologica Sinica"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00807-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-022-00807-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00807-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T09:21:46Z","timestamp":1672996906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-022-00807-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s13318-022-00807-3","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"assertion":[{"value":"10 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by grants from the Natural Science Foundation of Fujian Province of China (grant no. 2018Y0037, 2021J01761), Fujian Medical Innovation Project (grant no. 2019-CX-19), and Startup Fund for scientific research, Fujian Medical University (grant no. 2019QH1269).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study involves human participants who were following the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Ethics Committee of Fujian Medical University Union Hospital (2020YF022-01) approved this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the study participants before study commencement.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Conceptualization: Y.C., H.Q., and J.Z. Methodology: Y.C. and X.L. Data curation: Y.C., X.L., and J.C. Formal analysis and investigation: Y.C. and J.C. Writing: Y.C. Supervision: H.Q. and J.Z.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The coding for this study is available from the corresponding author upon reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}